AstraZeneca Unit Fights Amgen, Samsung Over Soliris Patent
An AstraZeneca subsidiary sought on Tuesday to prevent Amgen and Samsung Bioepis from selling drugs similar to its Soliris product, claiming at a London court that the two companies' drugs infringe...To view the full article, register now.
Already a subscriber? Click here to view full article